combined BRAF-MEK inhibitors
trametinib plus dabrafenib
mNSCLC - L2 - adenocarcinoma cell
mNSCLC - L2 - all population 5
mNSCLC - L2 - EGFR high
mNSCLC - L2 - EGFR mutant 1
mNSCLC - L2 - EGFR wild type
mNSCLC - L2 - KRAS mutant
mNSCLC - L2 - KRAS wild type
mNSCLC - L2 - PDL1 negative 1
mNSCLC - L2 - PDL1 positive 7
non squamous cell - mNSCLC - L2
non squamous - mNSCLC - L2 - all population 1
non squamous - mNSCLC - L2 - EGFR mutant
non squamous - mNSCLC - L2 - PDL1 positive
non squamous - mNSCLC - L2 - wild type (WT)
squamous cell - mNSCLC - L2
squamous - mNSCLC - L2 - all population 1
squamous - mNSCLC - L2 - PDL1 positive
Comparator:
Risk of bias:  low;   some concerns;   high;  NA;